Skip to content
10-K

Annual Report

UroGen Pharma Ltd. URGN

0001437749-26-006234

← back to feed
Filed
Mar 2, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 24, 2026 48.68M sh
Capex FY 2025 · Dec 31, 2025 $289K
Capex FY 2025 · Dec 31, 2024 $295K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$162.44M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$96.77M
Long Term Debt FY 2025 · Dec 31, 2025 $122.21M
Long Term Debt FY 2025 · Dec 31, 2024 $121.73M
Short Term Investments FY 2025 · Dec 31, 2025 $49.31M
Short Term Investments FY 2025 · Dec 31, 2024 $110.67M
Cash And Equivalents FY 2025 · Dec 31, 2025 $110.75M
Cash And Equivalents FY 2025 · Dec 31, 2024 $171.99M
Stockholders Equity FY 2025 · Dec 31, 2025 −$105.47M
Stockholders Equity FY 2025 · Dec 31, 2024 −$8.8M
Stockholders Equity FY 2025 · Dec 31, 2023 −$65.21M
Current Liabilities FY 2025 · Dec 31, 2025 $46.42M
Current Liabilities FY 2025 · Dec 31, 2024 $45.95M
Total Liabilities FY 2025 · Dec 31, 2025 $305.93M
Total Liabilities FY 2025 · Dec 31, 2024 $294.51M
Current Assets FY 2025 · Dec 31, 2025 $186.02M
Current Assets FY 2025 · Dec 31, 2024 $276.14M
Total Assets FY 2025 · Dec 31, 2025 $200.46M
Total Assets FY 2025 · Dec 31, 2024 $285.71M
Eps Basic FY 2025 · Dec 31, 2025 −$3.19
Eps Basic FY 2025 · Dec 31, 2024 −$2.96
Sga Expense FY 2025 · Dec 31, 2025 $155.1M
Sga Expense FY 2025 · Dec 31, 2024 $121.15M
Rd Expense FY 2025 · Dec 31, 2025 $67.11M
Rd Expense FY 2025 · Dec 31, 2024 $57.15M
Net Income FY 2025 · Dec 31, 2025 −$153.49M
Net Income FY 2025 · Dec 31, 2024 −$126.87M
Operating Income FY 2025 · Dec 31, 2025 −$124.86M
Operating Income FY 2025 · Dec 31, 2024 −$96.78M
Gross Profit FY 2025 · Dec 31, 2025 $97.34M
Gross Profit FY 2025 · Dec 31, 2024 $81.52M
Cost Of Revenue FY 2025 · Dec 31, 2025 $12.45M
Cost Of Revenue FY 2025 · Dec 31, 2024 $8.88M
Revenue FY 2025 · Dec 31, 2025 $109.79M
Revenue FY 2025 · Dec 31, 2024 $90.4M